Lexie B3 vs Resound Vivia 9 60S microRIE

The Lexie B3 is a behind-the-ear OTC hearing aid priced at $999 that earns an A grade with a SoundScore of 4.8/5 in our lab testing. This places it at #1 among the 65 OTC hearing aids we've evaluated, making it a standout performer in its category. In our standardized testing, the Lexie B3 demonstrates excellent speech-in-quiet performance at 4.5/5, scoring 1.73 points above the OTC category average of 2.79/5. Speech-in-noise results are more nuanced—while the 2.5/5 score sits 1.02 points above the category average of 1.48/5, this remains mixed in absolute terms. Music streaming quality is solid at 3.3/5, exceeding the category average by 1.38 points, and feedback handling is excellent at 4.6/5. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above the category average. The device uses a tulip dome coupling in both initial and tuned configurations, maintaining consistent performance across fitting conditions with identical normalized scores of 4.8/5 for both fits. For those considering alternatives, devices like the RxEars Rxi, Meta Ray-Ban Glasses (Gen 2), and Cearvol Wave offer lower price points, though with correspondingly lower SoundScores. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance who prioritize speech clarity in quieter environments and quality music streaming, and who can accommodate its mid-tier OTC price point.

The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, currently available at $3,798. In HearAdvisor's lab testing, it earned a B grade with a SoundScore of 3.9/5, ranking #27 of 36 prescription hearing aids tested. This device demonstrates a mixed performance profile in our testing. Own-voice comfort is a notable strength, scoring 3.4/5—a solid result that sits 0.65 points above the category average, which may appeal to users sensitive to the hollow or boomy sound of their own speech. Speech clarity in quiet environments also performs well at 3.4/5, slightly above the category average. However, the Vivia 9 shows significant limitations in challenging listening situations. Speech in noise scored just 1.1/5, falling 0.81 points below the prescription hearing aid average—a substantial gap that suggests difficulty in restaurants, group conversations, or other noisy environments. Feedback handling, while strong in absolute terms at 4.2/5, still lands 0.51 points below what we typically see from prescription devices. Music streaming quality is mixed at 2.6/5, essentially matching the category average. At this premium price point, the Vivia 9 faces stiff competition. Several same-priced alternatives, including the Phonak Sphere Infinio and Oticon Intent, achieved notably higher overall scores in our testing. Consumers prioritizing noise performance may want to explore these options or consider lower-priced alternatives like the Sennheiser All Day Clear that delivered stronger overall results in our lab.